Grace Therapeutics (GRCE) Common Equity (2017 - 2026)
Grace Therapeutics (GRCE) posted Common Equity of $63.9 million for Q1 2026, down 1.53% sequentially from $64.9 million in Q4 2025, and down 4.07% YoY from $66.6 million in Q1 2025.
Grace Therapeutics (GRCE) Common Equity (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Common Equity for 10 years, with the latest figure at $63.9 million in Q1 2026.
- Quarterly Common Equity fell 4.07% year-over-year to $63.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.9 million (down 4.07% YoY) and the FY2026 annual result came in at $63.9 million, down 4.07% from the prior year.
- Common Equity retreated to $63.9 million in Q1 2026 per GRCE's latest filing, from $64.9 million in the prior quarter.
- Over five years, Common Equity peaked at $108.3 million in Q1 2022 and troughed at $52.1 million in Q4 2024.
- A 5-year average of $72.0 million and a median of $64.7 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity jumped 95.3% in 2022, then sank 38.69% in 2023.
- Over 5 years, Common Equity stood at $96.7 million in 2022, then slumped by 33.13% to $64.7 million in 2023, then dropped by 19.39% to $52.1 million in 2024, then gained by 24.46% to $64.9 million in 2025, then retreated by 1.53% to $63.9 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $63.9 million, $64.9 million, and $62.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 9.79 Bn |
| 10 | Grace Therapeutics | 37.72 Mn | 37.72 Mn | - | 48.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.21 Mn |
| Mar 31, 2026 | 63.90 Mn |
| Dec 31, 2025 | 64.89 Mn |
| Sep 30, 2025 | 62.82 Mn |
| Jun 30, 2025 | 63.55 Mn |
| Mar 31, 2025 | 66.61 Mn |
| Dec 31, 2024 | 52.14 Mn |
| Sep 30, 2024 | 56.13 Mn |
| Jun 30, 2024 | 59.36 Mn |
| Mar 31, 2024 | 61.74 Mn |
| Dec 31, 2023 | 64.68 Mn |
| Sep 30, 2023 | 66.75 Mn |
| Jun 30, 2023 | 64.01 Mn |
| Mar 31, 2023 | 67.96 Mn |
| Dec 31, 2022 | 96.72 Mn |
| Sep 30, 2022 | 100.16 Mn |
| Jun 30, 2022 | 104.40 Mn |
| Mar 31, 2022 | 108.27 Mn |
| Dec 31, 2021 | 111.06 Mn |
| Sep 30, 2021 | 114.20 Mn |